Galilei Biosciences

SIRT6 activation, small molecules, neuroprotection

modulatingsmall molecule

Cambridge, Massachusetts, United States·

01Overview 02People 03Projects 04Concepts 05Patents 06Public records 07Belief evolution

Plate C · C-EHEV

Summary · Eternal Search editorial

Galilei Biosciences SIRT6 activation, small molecules, neuroprotection

Galilei Biosciences is developing proprietary small-molecule SIRT6 activators, with glaucoma identified as the primary indication. The deck states that SIRT6 activation has shown neuroprotective, anti-inflammatory, mitochondrial, metabolic, and DNA-repair effects. Its development plan focuses on medicinal chemistry, ADME/PK optimization, in vivo proof of concept, and development-candidate nomination for glaucoma.

The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong

Plate C·01 · Scientific profile

All 16 dimensions
on the record.

Composite16

Chain scale100 pts

Dimensions16

Plate C·02 · Where it sits among peers

Score vs. proximity
to longevity goals.

Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.

Reading

Galilei Biosciences — Early mechanism · Bottom quartile. Derived deterministically from 7 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Modifiers: +5 depth (7 programs at preclinical).…

Source: Deterministic

At a glance

HQCambridge, Massachusetts, United States

Publications

16 on file

012024Sirt6 protects retinal ganglion cells and optic nerve from degeneration during aging and glaucoma—

022024Hepatic Sirt6 activation abrogates acute liver failure—

032023Cartilage-specific Sirt6 deficiency represses IGF-1 and enhances osteoarthritis severity in mice—

042023Design, synthesis, and pharmacological evaluations of pyrrolo[1,2-a]quinoxaline-based derivatives as potent and selective sirt6 activators—

052023Sirtuin 6 activation rescues the age-related decline in DNA damage repair in primary human chondrocytes—

062022SIRT6 Mitigates Heart Failure With Preserved Ejection Fraction in Diabetes—

072022MDL-800, the SIRT6 Activator, Suppresses Inflammation via the NF-kB Pathway and Promotes Angiogenesis to Accelerate Cutaneous Wound Healing in Mice—

082022Unmet Needs in the Detection, Diagnosis, Monitoring, Treatment, and Understanding of Primary Open-Angle Glaucoma: A Position Statement of the American Glaucoma Society and the American Society of Cataract and Refractive Surgery—

092022The Immunological Effect of Oxygen Carriers on Normothermic Ex Vivo Liver Perfusion—

102021Restoration of energy homeostasis by SIRT6 extends healthy lifespan—

112020Biological and catalytic functions of sirtuin 6 as targets for small-molecule modulators—

122018Identification of a cellularly active SIRT6 allosteric activator—

132017Discovery of ^{72}Rb: A Nuclear Sandbank Beyond the Proton Drip Line.Physical review letters 142015Searching for Dark Matter Annihilation from Milky Way Dwarf Spheroidal Galaxies with Six Years of Fermi Large Area Telescope Data.Physical review letters 152014Inferred cosmic-ray spectrum from Fermi large area telescope γ-ray observations of Earth's limb.Physical review letters

162012The sirtuin SIRT6 regulates lifespan in male mice—

Loading

Loading section...

0-100 chain-logic scale · 15 dimensions · scored on public evidence

Galilei Biosciences

All 16 dimensionson the record.

Score vs. proximityto longevity goals.

Publications

Loading

All 16 dimensionson the record.

Score vs. proximityto longevity goals.

Publications

All 16 dimensions
on the record.

Score vs. proximity
to longevity goals.

All 16 dimensions
on the record.

Score vs. proximity
to longevity goals.